Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma

Foss, F. M., Kim, Y. H., Prince, H. M., Akilov, O. E., Querfeld, C., Seminario-Vidal, L., Fisher, D. C., Kuzel, T. M., Yannakou, C. K., Geskin, L. J., Feldman, T., Sokol, L., Allen, P. B., Dang, N. H., Cabanillas, F., Wong, H. K., Ooi, C. E., Xing, D., Sauter, N., … Duvic, M. (2024). Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco-24-01549
Authors:
Francine M Foss
Youn H Kim
H Miles Prince
Oleg E Akilov
Christiane Querfeld
Lucia Seminario-Vidal
David C Fisher
Timothy M Kuzel
Costas K Yannakou
Larisa J Geskin
Tatyana Feldman
Lubomir Sokol
Pamela Blair Allen
Nam Hoang Dang
Fernando Cabanillas
Henry K Wong
Chean Eng Ooi
Dongyuan Xing
Nicholas Sauter
Preeti Singh
Myron Czuczman
Madeleine Duvic
Affiliated Authors:
Larisa J Geskin
Publication Type:
Article
Unique ID:
10.1200/jco-24-01549
PMID:
Publication Date:
Data Source:
PubMed

Record Created: